Semin Neurol 2017; 37(02): 193-204
DOI: 10.1055/s-0037-1602246
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Botulinum Toxin Therapy for Parkinson's Disease

Aparna Wagle Shukla
1   Department of Neurology, University of Florida, University of Florida Center for Movement Disorders and Neurorestoration, Gainesville, Florida
,
Irene A. Malaty
1   Department of Neurology, University of Florida, University of Florida Center for Movement Disorders and Neurorestoration, Gainesville, Florida
› Author Affiliations
Further Information

Publication History

Publication Date:
16 May 2017 (online)

Abstract

Botulinum toxin (BoNT) therapy is frequently employed in the treatment of Parkinson's disease (PD) symptoms. It can effectively ameliorate the symptoms of cervical dystonia, blepharospasm, sialorrhea, and hyperactive bladder. It is increasingly being used for additional PD-related indications including limb dystonia, oromandibular dystonia, tremors, constipation, dysphagia, gastroparesis, and sweating dysfunction. Botulinum toxin treatment has mostly local side effects and does not interfere with dopaminergic therapies prescribed for PD. With the exception of dystonia and sialorrhea, most evidence for BoNT efficacy is derived from studies conducted in nonparkinsonian populations. Thus, the data to inform typical response pattern and side-effect profile in PD are still evolving. Nevertheless, BoNT is widely used and is an important tool in the PD-treatment arsenal. In this review, the authors discuss the current literature on the use of BoNT in various PD-related motor and nonmotor disorders.

 
  • References

  • 1 Peng Chen Z, Morris Jr JG, Rodriguez RL, Shukla AW, Tapia-Núñez J, Okun MS. Emerging opportunities for serotypes of botulinum neurotoxins. Toxins (Basel) 2012; 4 (11) 1196-1222
  • 2 Mills R, Bahroo L, Pagan F. An update on the use of botulinum toxin therapy in Parkinson's disease. Curr Neurol Neurosci Rep 2015; 15 (01) 511
  • 3 Brashear A. Clinical comparisons of botulinum neurotoxin formulations. Neurologist 2008; 14 (05) 289-298
  • 4 Marchetti A, Magar R, Findley L. , et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord 2005; 20 (08) 937-944
  • 5 Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord 2013; 28 (13) 1775-1783
  • 6 Hallett M, Benecke R, Blitzer A, Comella CL. Treatment of focal dystonias with botulinum neurotoxin. Toxicon 2009; 54 (05) 628-633
  • 7 Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton III LJ. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988; 3 (03) 188-194
  • 8 Rana AQ, Kabir A, Dogu O, Patel A, Khondker S. Prevalence of blepharospasm and apraxia of eyelid opening in patients with parkinsonism, cervical dystonia and essential tremor. Eur Neurol 2012; 68 (05) 318-321
  • 9 Martinez-Ramirez D, Giugni JC, Hastings E. , et al. Comparable botulinum toxin outcomes between primary and secondary blepharospasm: a retrospective analysis. Tremor Other Hyperkinet Mov (N Y) 2014; 4: 286
  • 10 Krack P, Marion MH. “Apraxia of lid opening,” a focal eyelid dystonia: clinical study of 32 patients. Mov Disord 1994; 9 (06) 610-615
  • 11 Hallett M, Albanese A, Dressler D. , et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 2013; 67: 94-114
  • 12 Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987; 37 (04) 616-623
  • 13 Girlanda P, Quartarone A, Sinicropi S, Nicolosi C, Messina C. Unilateral injection of botulinum toxin in blepharospasm: single fiber electromyography and blink reflex study. Mov Disord 1996; 11 (01) 27-31
  • 14 Truong D, Comella C, Fernandez HH, Ondo WG. ; Dysport Benign Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 2008; 14 (05) 407-414
  • 15 Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord 2011; 26 (08) 1521-1528
  • 16 Simpson DM, Hallett M, Ashman EJ. , et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2016; 86 (19) 1818-1826
  • 17 Roggenkämper P, Jost WH, Bihari K, Comes G, Grafe S, Team NTBS. ; NT 201 Blepharospasm Study Team. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm (Vienna) 2006; 113 (03) 303-312
  • 18 Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenkämper P. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm (Vienna) 2011; 118 (02) 233-239
  • 19 Saad J, Gourdeau A. A direct comparison of onabotulinumtoxina (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique. J Neuroophthalmol 2014; 34 (03) 233-236
  • 20 Nüssgens Z, Roggenkämper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 1997; 235 (04) 197-199
  • 21 Sampaio C, Ferreira JJ, Simões F. , et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1. Mov Disord 1997; 12 (06) 1013-1018
  • 22 Ochudlo S, Bryniarski P, Opala G. Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm. Parkinsonism Relat Disord 2007; 13 (08) 505-508
  • 23 Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotox Res 2009; 15 (03) 224-231
  • 24 Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon 2009; 54 (05) 614-623
  • 25 Forget R, Tozlovanu V, Iancu A, Boghen D. Botulinum toxin improves lid opening delays in blepharospasm-associated apraxia of lid opening. Neurology 2002; 58 (12) 1843-1846
  • 26 Jankovic J. Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening. J Neurol Neurosurg Psychiatry 1996; 60 (06) 704
  • 27 Kashihara K, Imamura T. Frequency and clinical correlates of retrocollis in Parkinson's disease. J Neurol Sci 2013; 324 (1-2): 106-108
  • 28 Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord 2006; 21 (11) 1856-1863
  • 29 Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 1991; 6 (02) 119-126
  • 30 Simpson DM, Blitzer A, Brashear A. , et al; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70 (19) 1699-1706
  • 31 Geenen C, Consky E, Ashby P. Localizing muscles for botulinum toxin treatment of focal hand dystonia. Can J Neurol Sci 1996; 23 (03) 194-197
  • 32 Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF. ; CD 140 Study Group. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol 2012; 35 (05) 208-214
  • 33 Poewe W, Deuschl G, Nebe A. , et al; German Dystonia Study Group. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J Neurol Neurosurg Psychiatry 1998; 64 (01) 13-17
  • 34 Truong D, Duane DD, Jankovic J. , et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005; 20 (07) 783-791
  • 35 Truong D, Brodsky M, Lew M. , et al; Global Dysport Cervical Dystonia Study Group. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 2010; 16 (05) 316-323
  • 36 Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S. , Group USXCDS; U.S. XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 2011; 308 (1-2): 103-109
  • 37 Brashear A, Lew MF, Dykstra DD. , et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999; 53 (07) 1439-1446
  • 38 Brin MF, Lew MF, Adler CH. , et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999; 53 (07) 1431-1438
  • 39 Lew MF, Adornato BT, Duane DD. , et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997; 49 (03) 701-707
  • 40 Brans JW, Lindeboom R, Snoek JW. , et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996; 46 (04) 1066-1072
  • 41 Pappert EJ, Germanson T. ; Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord 2008; 23 (04) 510-517
  • 42 Comella CL, Jankovic J, Shannon KM. , et al; Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005; 65 (09) 1423-1429
  • 43 Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002; 72 (04) 459-462
  • 44 Odergren T, Hjaltason H, Kaakkola S. , et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998; 64 (01) 6-12
  • 45 Patterson A, Almeida L, Hess CW. , et al. Occurrence of dysphagia following botulinum toxin injection in parkinsonism-related cervical dystonia: a retrospective study. Tremor Other Hyperkinet Mov (N Y) 2016; 6: 379
  • 46 Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G. “Off” painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord 1995; 10 (03) 333-336
  • 47 Singer C, Papapetropoulos S. Lower limb post-immobilization dystonia in Parkinson's disease. J Neurol Sci 2005; 239 (01) 111-114
  • 48 Cordivari C, Misra VP, Catania S, Lees AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord 2001; 16 (05) 907-913
  • 49 Gupta AD, Visvanathan R. Botulinum toxin for foot dystonia in patients with Parkinson's disease having deep brain stimulation: a case series and a pilot study. J Rehabil Med 2016; 48 (06) 559-562
  • 50 Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, de Haan RJ, Speelman JD. Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry 2007; 78 (03) 264-270
  • 51 Contarino MF, Kruisdijk JJ, Koster L, Ongerboer de Visser BW, Speelman JD, Koelman JH. Sensory integration in writer's cramp: comparison with controls and evaluation of botulinum toxin effect. Clin Neurophysiol 2007; 118 (10) 2195-2206
  • 52 Yoshimura DM, Aminoff MJ, Olney RK. Botulinum toxin therapy for limb dystonias. Neurology 1992; 42 (3 Pt 1): 627-630
  • 53 Tsui JK, Bhatt M, Calne S, Calne DB. Botulinum toxin in the treatment of writer's cramp: a double-blind study. Neurology 1993; 43 (01) 183-185
  • 54 Cole R, Hallett M, Cohen LG. Double-blind trial of botulinum toxin for treatment of focal hand dystonia. Mov Disord 1995; 10 (04) 466-471
  • 55 Tassorelli C, De Icco R, Alfonsi E. , et al. Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: a placebo controlled study. Parkinsonism Relat Disord 2014; 20 (11) 1140-1144
  • 56 Ekbom K, Lindholm H, Ljungberg L. New dystonic syndrome associated with butyrophenone therapy. Z Neurol 1972; 202 (02) 94-103
  • 57 Azher SN, Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology 2005; 65 (03) 355-359
  • 58 Wijemanne S, Jimenez-Shahed J. Improvement in dystonic camptocormia following botulinum toxin injection to the external oblique muscle. Parkinsonism Relat Disord 2014; 20 (10) 1106-1107
  • 59 von Coelln R, Raible A, Gasser T, Asmus F. Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord 2008; 23 (06) 889-892
  • 60 Bonanni L, Thomas A, Varanese S, Scorrano V, Onofrj M. Botulinum toxin treatment of lateral axial dystonia in Parkinsonism. Mov Disord 2007; 22 (14) 2097-2103
  • 61 Santamato A, Ranieri M, Panza F. , et al. Botulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson's disease. J Neurol 2010; 257 (01) 139-141
  • 62 Dupeyron A, Viollet E, Coroian F, Gagnard C, Renard D, Castelnovo G. Botulinum toxin-A for treatment of Pisa syndrome: A new target muscle. Parkinsonism Relat Disord 2015; 21 (06) 669-670
  • 63 Bruno VA, Fox SH, Mancini D, Miyasaki JM. Botulinum toxin use in refractory pain and other symptoms in parkinsonism. Can J Neurol Sci 2016; 43 (05) 697-702
  • 64 Tan EK, Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc 2000; 131 (02) 211-216
  • 65 Schneider SA, Edwards MJ, Cordivari C, Macleod WN, Bhatia KP. Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson's disease. Mov Disord 2006; 21 (10) 1722-1724
  • 66 Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord 1996; 11 (03) 250-256
  • 67 Trosch RM, Pullman SL. Botulinum toxin A injections for the treatment of hand tremors. Mov Disord 1994; 9 (06) 601-609
  • 68 Henderson JM, Ghika JA, Van Melle G, Haller E, Einstein R. Botulinum toxin A in non-dystonic tremors. Eur Neurol 1996; 36 (01) 29-35
  • 69 Rahimi F, Samotus O, Lee J, Jog M. Effective management of upper limb parkinsonian tremor by incobotulinumtoxina injections using sensor-based biomechanical patterns. Tremor Other Hyperkinet Mov (N Y) 2015; 5: 348
  • 70 Espay AJ, Vaughan JE, Shukla R. et al. Botulinum toxin type A for levodopa-induced cervical dyskinesias in Parkinson's disease: unfavorable risk-benefit ratio. Mov Disord 2011; 26 (05) 913-914
  • 71 Srivanitchapoom P, Pandey S, Hallett M. Drooling in Parkinson's disease: a review. Parkinsonism Relat Disord 2014; 20 (11) 1109-1118
  • 72 Chou KL, Evatt M, Hinson V, Kompoliti K. Sialorrhea in Parkinson's disease: a review. Mov Disord 2007; 22 (16) 2306-2313
  • 73 Bateson MC, Gibberd FB, Wilson RS. Salivary symptoms in Parkinson disease. Arch Neurol 1973; 29 (04) 274-275
  • 74 Proulx M, de Courval FP, Wiseman MA, Panisset M. Salivary production in Parkinson's disease. Mov Disord 2005; 20 (02) 204-207
  • 75 Nicaretta DH, de Rosso AL, Maliska C, Costa MM. Scintigraphic analysis of the parotid glands in patients with sialorrhea and Parkinson's disease. Parkinsonism Relat Disord 2008; 14 (04) 338-341
  • 76 Leibner J, Ramjit A, Sedig L. , et al. The impact of and the factors associated with drooling in Parkinson's disease. Parkinsonism Relat Disord 2010; 16 (07) 475-477
  • 77 Edwards LL, Pfeiffer RF, Quigley EM, Hofman R, Balluff M. Gastrointestinal symptoms in Parkinson's disease. Mov Disord 1991; 6 (02) 151-156
  • 78 Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 2002; 17 (06) 1318-1320
  • 79 Bushara KO. Sialorrhea in amyotrophic lateral sclerosis: a hypothesis of a new treatment--botulinum toxin A injections of the parotid glands. Med Hypotheses 1997; 48 (04) 337-339
  • 80 Bhatia KP, Münchau A, Brown P. Botulinum toxin is a useful treatment in excessive drooling in saliva. J Neurol Neurosurg Psychiatry 1999; 67 (05) 697
  • 81 Jost WH. Treatment of drooling in Parkinson's disease with botulinum toxin. Mov Disord 1999; 14 (06) 1057
  • 82 Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000; 54 (01) 244-247
  • 83 Friedman A, Potulska A. Botulinum toxin for treatment of parkinsonian sialorrhea. Neurol Neurochir Pol 2001; 35 (Suppl. 03) 23-27
  • 84 Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003; 61 (09) 1279-1281
  • 85 Mancini F, Zangaglia R, Cristina S. , et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 2003; 18 (06) 685-688
  • 86 Racette BA, Good L, Sagitto S, Perlmutter JS. Botulinum toxin B reduces sialorrhea in parkinsonism. Mov Disord 2003; 18 (09) 1059-1061
  • 87 Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004; 62 (01) 37-40
  • 88 Dogu O, Apaydin D, Sevim S, Talas DU, Aral M. Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 2004; 106 (02) 93-96
  • 89 Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006; 21 (05) 704-707
  • 90 Contarino MF, Pompili M, Tittoto P. , et al. Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease. Parkinsonism Relat Disord 2007; 13 (05) 299-303
  • 91 Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol 2009; 256 (04) 563-567
  • 92 Steinlechner S, Klein C, Moser A, Lencer R, Hagenah J. Botulinum toxin B as an effective and safe treatment for neuroleptic-induced sialorrhea. Psychopharmacology (Berl) 2010; 207 (04) 593-597
  • 93 Guidubaldi A, Fasano A, Ialongo T. , et al. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Mov Disord 2011; 26 (02) 313-319
  • 94 Chinnapongse R, Gullo K, Nemeth P, Zhang Y, Griggs L. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial. Mov Disord 2012; 27 (02) 219-226
  • 95 Jost WH. The option of sonographic guidance in botulinum toxin injection for drooling in Parkinson's disease. J Neural Transm (Vienna) 2016; 123 (01) 51-55
  • 96 Petracca M, Guidubaldi A, Ricciardi L. , et al. Botulinum toxin A and B in sialorrhea: long-term data and literature overview. Toxicon 2015; 107 (Pt A): 129-140
  • 97 Pinnington LL, Muhiddin KA, Ellis RE, Playford ED. Non-invasive assessment of swallowing and respiration in Parkinson's disease. J Neurol 2000; 247 (10) 773-777
  • 98 Bushmann M, Dobmeyer SM, Leeker L, Perlmutter JS. Swallowing abnormalities and their response to treatment in Parkinson's disease. Neurology 1989; 39 (10) 1309-1314
  • 99 Bird MR, Woodward MC, Gibson EM, Phyland DJ, Fonda D. Asymptomatic swallowing disorders in elderly patients with Parkinson's disease: a description of findings on clinical examination and videofluoroscopy in sixteen patients. Age Ageing 1994; 23 (03) 251-254
  • 100 Mari F, Matei M, Ceravolo MG, Pisani A, Montesi A, Provinciali L. Predictive value of clinical indices in detecting aspiration in patients with neurological disorders. J Neurol Neurosurg Psychiatry 1997; 63 (04) 456-460
  • 101 Gui D, Rossi S, Runfola M, Magalini SC. Review article: botulinum toxin in the therapy of gastrointestinal motility disorders. Aliment Pharmacol Ther 2003; 18 (01) 1-16
  • 102 Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kalloo AN. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med 1995; 332 (12) 774-778
  • 103 Gil RA, Hwynn N, Fabian T, Joseph S, Fernandez HH. Botulinum toxin type A for the treatment of gastroparesis in Parkinson's disease patients. Parkinsonism Relat Disord 2011; 17 (04) 285-287
  • 104 Abbott RD, Ross GW, White LR. , et al. Environmental, life-style, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. J Neurol 2003; 250 (Suppl. 03) III30-III39
  • 105 Brisinda G, Bentivoglio AR, Maria G, Albanese A. Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms. Mov Disord 2004; 19 (08) (Suppl. 08) S146-S156
  • 106 Mathers SE, Kempster PA, Swash M, Lees AJ. Constipation and paradoxical puborectalis contraction in anismus and Parkinson's disease: a dystonic phenomenon?. J Neurol Neurosurg Psychiatry 1988; 51 (12) 1503-1507
  • 107 Albanese A, Brisinda G, Bentivoglio AR, Maria G. Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. Am J Gastroenterol 2003; 98 (06) 1439-1440
  • 108 Cadeddu F, Bentivoglio AR, Brandara F, Marniga G, Brisinda G, Maria G. Outlet type constipation in Parkinson's disease: results of botulinum toxin treatment. Aliment Pharmacol Ther 2005; 22 (10) 997-1003
  • 109 Sakakibara R, Odaka T, Uchiyama T. , et al. Colonic transit time and rectoanal videomanometry in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74 (02) 268-272
  • 110 Sakakibara R, Shinotoh H, Uchiyama T. , et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci 2001; 92 (1-2): 76-85
  • 111 Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. J Urol 2009; 182 (04) 1453-1457
  • 112 Giannantoni A, Conte A, Proietti S. , et al. Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder. J Urol 2011; 186 (03) 960-964
  • 113 Naumann M, So Y, Argoff CE. , et al; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70 (19) 1707-1714
  • 114 Anderson RU, Orenberg EK, Glowe P. OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson's disease. Urology 2014; 83 (01) 22-27
  • 115 Jiang YH, Liao CH, Tang DL, Kuo HC. Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder. PLoS One 2014; 9 (08) e105989
  • 116 Swinn L, Schrag A, Viswanathan R, Bloem BR, Lees A, Quinn N. Sweating dysfunction in Parkinson's disease. Mov Disord 2003; 18 (12) 1459-1463
  • 117 Molloy FM, Shill HA, Kaelin-Lang A, Karp BI. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. Neurology 2002; 58 (05) 805-807
  • 118 Naumann M, Carruthers A, Carruthers J. , et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord 2010; 25 (13) 2211-2218